Azelastine hydrochloride
Azelastine HCl is a potent, second-generation, selective, histamine antagonist. (In Vitro) :Azelastine hydrochloride can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling. (In Vivo) :Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model.Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model.
Product Specifications
CAS Number
79307-93-0
Product Name Alternative
Azelastine HCl | Astelin | Optivar | Allergodil | Rhinolast | Azeptin
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Ethanol: 84 mg/mL (200.78 mM) ; Water: 35 mg/mL (83.66 mM) ; DMSO: 84 mg/mL (200.78 mM)
Smiles
CN1CCCC (CC1) N2C (=O) C3=CC=CC=C3C (=N2) CC4=CC=C (C=C4) Cl.Cl
Molecular Formula
C22H24ClN3O·HCl
Molecular Weight
418.36
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
4-[ (4-chlorophenyl) methyl]-2- (1-methylazepan-4-yl) phthalazin-1-one; hydrochloride
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-human SIRPa / CD172a (Hospital for Sick Children patent Anti-SIRPA Biosimilar)
Anti-human SIRPa / CD172a (Hospital for Sick Children patent Anti-SIRPA Biosimilar)